MicroRNAs are short regulatory RNAs that negatively modulate gene expression at the post-transcriptional level, and are deeply involved in the pathogenesis of several types of cancers. To investigate whether specific miRNAs and their target genes participate in the molecular pathogenesis of laryngeal carcinoma, oligonucleotide microarrays were used to assess the differential expression profiles of microRNAs and mRNAs in laryngeal carcinoma tissues compared with normal tissues. The oncogenic miRNA, microRNA-21 (miR-21), was found to be upregulated in laryngeal carcinoma tissues. Knockdown of miR-21 by specific antisense oligonucleotides inhibited the proliferation potential of HEp-2 cells, whereas overexpression of miR-21 elevated growth activity of the cells, as detected by the colony formation assay. The cell number reduction caused by miR-21 inhibition was due to the loss of control of the G1-S phase transition, instead of a noticeable increase in apoptosis. Subsequently, a new target gene of miR-21, BTG2, was found to be downregulated in laryngeal carcinoma tissues. BTG2 is known to act as a pan-cell cycle regulator and tumor suppressor. These findings indicate that aberrant expression of miR-21 may contribute to the malignant phenotype of laryngeal carcinoma by maintaining a low level of BTG2. The identification of the oncogenic miR-21 and its target gene, BTG2, in laryngeal carcinoma is potentially valuable for cancer diagnosis and therapy.
Introduction
MicroRNAs (miRNAs) are a group of non-coding, single-stranded RNAs that are approximately 22 nt in length. They regulate gene expression at the post-transcriptional level, and are involved in the regulation of cellular differentiation, development and metabolic processes. Hundreds of miRNAs have been identified in various mammalian genomes. To date, there have been 706 miRNA genes described in the human genome. It is becoming apparent that miRNAs have the potential to regulate at least 20%-30% of all human genes [1] , but their biological function remains largely unknown. Recently, researchers have uncovered both the tumor-suppressive and oncogenic potential of a number of miRNAs, underscoring their importance in human cancers [2] [3] [4] . In fact, either a single miRNA or small sets of miRNAs have been demonstrated to be dysregulated in diverse cancer subtypes. Aberrant expression of miRNAs can contribute to tumor development and progression by targeting certain tumor suppressor genes. Tumor suppressors maintain cell cycle checkpoint integrity and regulate apoptotic responses, and the deregulation of tumor suppressor genes by miRNAs can enhance tumorigenesis and contribute to poor clinical outcomes. Mertens-Talcott et al. [5] have reported that miR-27a facilitates cancer cell proliferation through the suppression of Myt-1, which blocks the cell cycle transition at G2-M. Moreover, miR-221 and miR-222 have also been found to be oncogenes that control cell cycle progression by inhibiting p27 kip1 [6, 7] . Laryngeal carcinoma is one of the most common head and neck cancers. Although early-stage laryngeal cancer is often curable with surgery or radiotherapy, for the majority of patients with the advanced disease, the outcome has not improved dramatically in the last two decades despite therapeutic advances. In order to further improve survival rates and treatments, it is important to better understand the mechanisms of carcinogenesis. Despite the fact that considerable efforts have been made in recent years, the molecular mechanism involved in the initiation and progression of laryngeal carcinoma remains largely unknown.
This study utilized an oligonucleotide microarray to examine the differential expression profiles of microRNAs and mRNAs in laryngeal carcinoma tissues compared to their adjacent normal tissues. MicroRNA-21 (miR-21), a known oncogenic miRNA, was found to be overexpressed in laryngeal carcinoma tissues, and suppression of miR-21 inhibited the proliferation of the cells of laryngeal carcinoma cell line, HEp-2, by suppressing cell cycle progression without affecting cell apoptosis. Deregulation of BTG2, which was identified to be a miR-21 target gene, may be responsible for the miR-21-mediated abnormal cellular phenotype.
Results

Differential miRNA expression between laryngeal carcinoma and normal laryngeal tissues
Using the miRNA microarray containing 210 human miRNA probe sets, we first assessed the miRNA profiles in three paired laryngeal carcinoma and normal laryngeal tissues. A miRNA was considered to be significantly upregulated only if the fold-change was more than 1.5 in the cancer tissues compared with the normal tissues. Likewise, only if a fold-change was less than 0.66 was the miRNA considered to be significantly downregulated. Statistical analysis identified 13 miRNAs that were differentially expressed in all three tumor tissues compared with the matched non-neoplastic controls. Among these 13 miRNAs, 6 miRNAs (let-7a-1, miR-203, miR-205, miR-21, miR-98 and miR-16-1) were upregulated and 7 miRNAs (miR-100, miR-1-2, miR-122a, miR-143, miR-145, miR-26a-1 and miR-34c) were downregulated in laryngeal carcinoma tissues (Table 1) . Among them, miR-21 is reported to be overexpressed in many types of solid tumors, including glioblastoma and breast cancer [8] [9] [10] [11] . Thus, we selected miR-21 for further studies.
The effect of miR-21 on the growth of HEp-2 cells
To study the biological significance of elevated miR-21 levels in laryngeal carcinoma cells, we first used a loss-of-function approach by transfecting the laryngeal carcinoma cell line, HEp-2, with chemically synthesized oligonucleotides complementary to miR-21. Transient transfection of HEp-2 cells with miR-21 ASO (specific antisense oligonucleotide of miR-21) caused suppression of cellular proliferation at 48-h and 72-h post-transfection in the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide) assay ( Figure 1A ). Meanwhile, the soft agar colony formation assay indicated that the number of colonies from HEp-2 cells transfected with miR-21 ASO was significantly lower than that of the negative control group ( Figure 1B) and that overexpression of miR-21 using a miR-21-expressing construct (pSilencer/sh-miR-21) led to elevated colony formation in tumor cells ( Figure 1C ). In addition, we also explored the effect of miR-21 on laryngeal tumorigenesis in vivo. Compared with the control group, knockdown of miR-21 led to suppression of overall tumor growth in nude mice ( Figure 1D) . Furthermore, the validity of the alterations of miR-21 expression levels was confirmed using realtime PCR assays ( Figure 1E ). These data indicate that the aberrant expression of miR-21 in laryngeal carcinoma may contribute to the malignant phenotype.
Suppression of miR-21 impairs the HEp-2 cell cycle without affecting apoptosis
To explore how the suppression of miR-21 inhibits HEp-2 cell growth, we studied the effects of miR-21 on cell cycle and cell apoptosis. The cell cycle distribution of HEp-2 cells was found to be affected by miR-21. The miRNA microarray analysis was performed to detect the dif- 
BTG2 is downregulated in laryngeal carcinoma and is a putative target of miR-21
MicroRNAs regulate a variety of cellular activities through regulation of the expression of multiple target genes. To understand the mechanism of miR-21-mediated cell cycle dysregulation in laryngeal carcinoma, we next focused on the identification of target genes that may participate in this process. As miR-21 has been validated as being elevated in laryngeal carcinoma, its target genes should be correspondingly downregulated in laryngeal carcinoma. The 7 267-spot human cDNA microarray was used to investigate the gene expression profiles of the three paired laryngeal carcinoma tissues compared with the adjacent normal tissues. As a result, 90 genes were found to be differentially expressed in the laryngeal carcinoma tissue. Among these genes, 29 were upregulated and 61, including BTG2, were downregulated. In order to find miR-21 target genes, we combined the datasets obtained from our microarray analysis with the datasets obtained from publicly available databases. It is well known Control ASO miR-21 ASO P < 0.01
Proliferation index (PI) [12, 13] . BTG2, a pan-cell cycle regulator that is confirmed to be downregulated in laryngeal carcinoma using semiquantitative RT-PCR, was predicted to be a target gene of miR-21 ( Figure 3A ).
MiR-21 regulates BTG2 at both the mRNA and the protein levels
To determine the effect of miR-21 on BTG2 expression levels, total RNA and protein were isolated from HEp-2 cells transfected with miR-21 ASO or control ASO. The mRNA level of BTG2 was quantified using semi-quantitative RT-PCR, and the protein level of BTG2 was detected by western blot. The results showed that both the mRNA and the protein levels of BTG2 were elevated in HEp-2 cells transfected with miR-21 ASO compared with cells transfected with control ASO ( Figure   Figure 3 Figure 3C ). In addition, when BTG2 protein was overexpressed in HEp-2 cells, a band with higher intensity was detected in western blot, demonstrating the specificity of the anti-BTG2 antibody ( Figure 3D ).
Direct effect of miR-21 on the 3′UTR of BTG2
An EGFP (enhanced green fluorescent protein) reporter assay was used to demonstrate that the negative regulation of miR-21 on BTG2 expression was direct. The alignment of miR-21 with the BTG2 3′UTR is illustrated in Figure 4A . The 3′UTR sequence of BTG2 was cloned downstream of the EGFP gene. We found that the expression of EGFP was strongly increased when miR-21 function was inhibited by transfecting cells with an antisense oligonucleotide ( Figure 4B ), whereas miR-21 overexpression reduced EGFP expression ( Figure 4C ). To further substantiate a direct effect of miR-21 on the BTG2 3′UTR, we introduced a triple mutation in the seed sequence of the BTG2 3′UTR complementary to miR-21. The EGFP expression from the mutated vector, pcDNA3/ EGFP-BTG2MUT, was not affected by miR-21, regardless of its expression levels ( Figure 4B and 4C) . We thus conclude that miR-21 regulates BTG2 expression directly through the UTR-binding region.
Discussion
MicroRNAs are a novel class of regulatory molecules with the ability to control gene expression at the posttranscriptional level. MiRNAs appear to decrease protein production either by increasing the degradation of mRNA or by blocking translation of mRNA into protein.
Hence, changes in the expression of even a single miR-NA may lead to changes in diverse cellular activities, which may contribute to the development of diseases. In the present study, miRNA microarray assay was used to assess the miRNA expression profiles of three laryngeal carcinoma tissues compared to their matched normal tissues. A total of 13 miRNAs were identified to be differentially expressed. Of the six upregulated miRNAs, miR-21 is known as an oncomir It is overexpressed in many types of tumor tissues, and contributes to malignant phenotypes [8] [9] [10] [11] . High expression of miR-21 in laryngeal carcinoma tissues may also correlate with tumor development and progression. In our study, suppression of miR-21 in cultured HEp2 cells decreased tumor cell npg growth suppression by miR-21 inhibition was found to be due to the loss of control of the G1-S phase transition, and not due to an increase in cell apoptosis, as shown by flow cytometry and cell apoptosis assay.
It is now well known that miRNAs regulate a variety of cellular activities through their effect on the expression of multiple target genes [14] . Identification of the target genes of miRNAs may help to characterize the diverse functions of miRNAs. Recent reports have found that PTEN, TPM1 and PDCD4 are target genes of miR-21 [15] [16] [17] [18] . However, given that a single miRNA has multiple targets, we believe that miR-21 also has other targets. Target prediction and validation are still challenges in miRNA research. Since the regulation of gene expression at the mRNA level may be a common mechanism for miRNA function, it is convenient to monitor transcriptional changes using a high-throughput approach such as a microarray [19] . Combining target prediction and expression profiling has been shown to be effective [20] . According to the results of the gene expression array from the three paired normal and cancer tissues, 29 genes were upregulated and 61 genes were downregulated in laryngeal carcinoma. Furthermore, the previously confirmed targets of miR-21, including PTEN, TPM1 and PDCD4, also showed a downregulation trend in at least one of the cDNA microarrays, demonstrating that microarray analysis is a valid method to help find miRNA targets. As a new candidate target gene of miR-21, BTG2 is downregulated in laryngeal carcinoma, and meanwhile, it is predicted to be a target gene of miR-21 according to publicly available databases.
Several results indicate that BTG2 is a target of miR-21. First, the 3′UTR of BTG2 contains a sequence matching the miR-21 seed region. Second, suppression of miR-21 caused enhanced expression of a BTG2 3′UTR-containing fluorescent reporter in HEp2 cells, whereas miR-21 overexpression reduced the EGFP level. Third, a site mutation in the BTG2 3′UTR complementary to miR-21 abolished miR-21 regulation. Finally, the mRNA and protein levels of BTG2 in HEp-2 cells were specifically correlated with the expression level of miR-21. An interesting fact is that the extent of change of BTG2 protein is more obvious than that of BTG2 mRNA. A possible explanation is that aside from mRNA degradation, the transcriptional repression mechanism also contributes to the regulation of BTG2 by miR-21. Recently, using array expression analysis, Frankel et al. [17] also found upregulation of BTG2 in MCF-7 cells depleted of miR-21. In short, miR-21 regulates BTG2 expression directly by binding to its 3′UTR.
The BTG2 belongs to an anti-proliferative gene family, which is highly conserved among various species.
Many potential roles of BTG2 have been suggested, such as a transcriptional co-regulator, a differentiation and anti-apoptotic factor in neurogenesis, a key mediator of the stage-specific expansion of thymocytes, a negative regulator of hematopoietic progenitor expansion, and a tumor suppressor in both mice and humans [21] . It has been found that the expression of BTG2 is constitutive and high in the thymus, lung alveolar epithelium, proximal tubule of the kidney and basal cell layer of prostate acini, whereas the mRNA level of BTG2 is usually low in their corresponding tumors [21] [22] [23] [24] [25] . Our research also validated the downregulation of BTG2 in laryngeal carcinomas by microarray and semi-quantitative RT-PCR. The loss of BTG2 expression may play an important role in the carcinogenic process. Aberrant expression of miR-21 may account for the repression of BTG2 levels in laryngeal carcinoma, although other mechanisms cannot be excluded.
In addition, BTG2, as a pan-cell cycle regulator, induces G1-S arrest via pRB-dependent and pRB-independent pathways [26, 27] . The former is carried out through the inhibition of cyclin D1 expression, and the latter by delayed biosynthesis of cyclin E and CDK4 proteins [21, 26, 27] . Thus, the identification of BTG2 as a miR-21 target gene provides a possible explanation as to why the suppression of miR-21 can inhibit the growth of tumor cells through influencing their cell cycles. As low pRB expression is frequently found in laryngeal carcinoma, suppression of miR-21 may induce G1-S arrest, mainly through a pRB-independent pathway, by upregulating the levels of BTG2 [27, 28] . However, further study is necessary to gain a full understanding of the underlying molecular mechanism.
Recently, aberrant expression of miR-21 has been found to contribute to the malignant phenotype by blocking the expression of critical apoptosis-related genes [10, 11] . Our research indicates that miR-21 suppression inhibits the growth of HEp2 cells without affecting apoptosis. Thus, loss of cell cycle control may be the potential mechanism of miR-21-mediated tumorigenesis in laryngeal carcinoma. Emerging evidence suggests that some miRNA activities influence cell cycle progression [5] [6] [7] 29] . Alteration of miRNA levels can thus contribute to pathological phenotypes by regulating cell cycle-related genes.
In conclusion, miR-21 functions as an oncomir and is overexpressed in laryngeal carcinoma tissues compared to their adjacent normal tissues. Suppression of miR-21 represses cell growth, possibly through inhibition of the cell cycle by targeting BTG2, but not through a marked increase in apoptosis. Thus, the identification of the oncogene, miR-21, and its target gene, BTG2, in laryngeal 835 npg carcinoma may help us to understand the molecular mechanism of tumorigenesis, and may have diagnostic and therapeutic values in the future.
Materials and Methods
Laryngeal carcinoma specimens, cell lines and isolation of RNAs
Laryngeal carcinoma specimens were collected from the Tianjin First Center Hospital. The paired fresh samples from tumor tissues and adjacent normal tissues were obtained from patients with sporadic laryngeal carcinoma undergoing surgical resection. The samples were snap-frozen in liquid nitrogen and stored at −80 °C. The laryngeal carcinoma cell line, HEp-2, was cultured at 37 °C with 5% CO 2 in RPMI-1640 media supplemented with 10% FBS, 100 U/ml penicillin and 100 μg/ml streptomycin. Total RNA and enriched small RNAs were obtained from the tissues using the mirVana miRNA Isolation Kit (Ambion, Austin, TX, USA) according to the manufacturer's recommendations. Total RNA was extracted from HEp-2 cells using the TRIzol reagent (Invitrogen, CA, USA).
MiRNA microarray analysis
A total of 210 DNA oligonucleotide probes from the mirVana miRNA Probe Set (Ambion) were designed according to the sequence of their respective mature miRNAs. Probes were resuspended at 50 mM in 3× saline sodium citrate (SSC) and spotted on MICROMAX Glass Slides SuperChip I (PerkinElmer, MA, USA) in duplicates at 50~60% humidity by the SpotArray 24 Microarray Printing System (PerkinElmer). Small RNAs were labeled with Cy5 or Cy3 dyes (Amersham Biosciences, Piscataway, NJ, USA) using the mirVana miRNA Labeling Kit (Ambion). After hybridization at 42 °C overnight (12-16 h), the slides were washed in SSC, and scanned with a ScanArray Express Microarray Scanner using ScanArray 3.0 software (PerkinElmer).
cDNA microarray analysis
The mRNAs from the three paired tumor and normal tissues were reverse transcribed using the MICROMAX TSA Labeling and Detection Kit (PerkinElmer), and the resulting cDNAs were labeled with fluorescein or biotin. Labeled cDNAs were purified and hybridized to DNA arrays containing 7 267 human genes relating to human cancer, apoptosis, signal transduction and liver enzymes (Qiagen Inc., CA, USA). Data normalization and calculation of expression values were performed using the ScanArray Express Microarray Analysis System (PerkinElmer).
Vector construction
The miR-21-expressing vector (pSilencer/sh-miR-21) was constructed according to the manufacturer's instructions for pSilencer 2.1 neo (Ambion). The plasmid expresses a miRNA hairpin that can be processed by the cellular machinery into mature miR-21. The negative control pSilencer 2.1 neo vector (pSilencer/NC) expresses a hairpin siRNA with limited homology to all known sequences in the human genome.
To construct the BTG2 expression vector, the fragment of BTG2 (GenBank accession No. NM_006763) coding region was amplified by RT-PCR from the cDNA library of normal laryngeal tissues using primers BTG2 sense, 5′-CGG AAT TCC GCG ACA TGA GCC ACG GGA AG-3′; and BTG2 antisense, 5′-GCA GCT CGA GGC CTA GCT GGA GAC TGC CAT C-3′. The amplified fragment was cloned into pcDNA3 at EcoRI and XhoI sites to form the pcDNA3/BTG2 vector.
To construct the fluorescence reporter plasmids, the EGFP gene from the pEGFP-N2 vector (Clontech, Mountain View, CA, USA) was subcloned into pcDNA3 and this is referred to as pcDNA3/ EGFP. The pcDNA3/EGFP-BTG2 reporter plasmid was constructed as follows: the 3′UTR sequence of BTG2 was obtained by RT-PCR from cDNA library of normal laryngeal tissues using specific primers (BTG2 UTR forward: 5′-CTA GGA TCC AGC CTC ATG GTC TC-3′; and BTG2 UTR reverse: 5′-GGC GAA TTC AGT AAC CTT TGT CTT-3′) containing the EcoRI and BamHI endonuclease recognition sites. This fragment was cloned into the pcD-NA3/EGFP vector at the EcoRI and BamHI sites, downstream of the EGFP gene. We also constructed pcDNA3/EGFP-BTG2MUT, a plasmid with a triple point mutation (TAAGCTA was mutated to TTACGTA) in the seed sequence of pcDNA3/EGFP-BTG2.
Transfection
The HEp-2 cells were transfected with oligonucleotides or plasmids using Lipofectamine 2000 reagent (Invitrogen) at 24 h after plating. Transfection complexes were prepared according to the manufacturer's instructions. The final oligonucleotide concentration was 10 nM, and the final plasmid concentration was 0.5 mg/ l. The transfection medium was replaced at 4-h post-transfection. The oligonucleotides complementary to miRNAs were synthesized by IDT (Coralville, IA, USA) and their sequences were as follows: miR-21 antisense oligonucleotide (miR-21 ASO): 5′-TCA ACA TCA GTC TGA TAA GCT A-3′; and negative control oligonucleotide (control ASO): 5′-GTG GAT ATT GTT GCC ATC A-3′.
Cell proliferation assay
After transfection, the HEp-2 cells were seeded in 96-well plates at 5 000 cells per well. The MTT assay was used to determine relative cell viability at 24 h, 48 h and at 96 h. 10 μl of MTT solution was added to 100 μl of culture media and incubated for 4 h at 37 °C, and the optical density was measured at 570 nm. Each experiment was performed in triplicates.
Soft agar colony formation assay
Anchorage-independent growth was determined by soft agar analysis as follows. 48 h after transfection, the HEp-2 cells (500 cells per well) were suspended in soft agar medium (RPMI-1640 media containing 0.3% agar) and seeded onto a base of RPMI-1640 media containing 0.5% agar in six-well plates. Plates were incubated at 37 °C, 5% CO 2 in a humidified incubator for 2 weeks. Colonies were counted under a microscopic field at ×100 magnification. Each assay was performed in triplicates.
Flow cytometry analysis
At 48 h after transfection with miR-21 ASO or control ASO, the HEp-2 cells were detached from the plates by trypsin incubation, rinsed with PBS and fixed in 70% (v/v) ethanol. The cells were then rehydrated in PBS and incubated with RNase (100 μg/ml) and propidium iodide (60 μg/ml) (Sigma-Aldrich, MO, USA). Cells were analyzed using the FACSCalibur System (BD Biosciences, San Jose, CA, USA), and the cell cycle phase was determined by 836 npg Cell Quest analysis. The proliferation index (PI) was calculated as follows: PI = (S+G2/M)/G1 (S, G2/M and G1 refer to the percentage of cells in S phase, G2/M phase and G1 phase, respectively.) [30] .
Cell apoptosis analysis
HEp-2 cells were transfected with miR-21 ASO or control ASO, and seeded into triplicate wells on a 14-well slide (CelLine/Erie Scientific Co., NH, USA) at 48-h post-transfection. HEp-2 cells cultured in complete medium, including 0.09 mg/ml teniposide (VM-26), an apoptosis inducer, were taken as positive control. HEp-2 cells cultured only in complete medium were taken as negative control. Cell apoptosis was detected by the In situ Cell Death Detection Kit, Fluorescein (Roche Applied Science, IN, USA) according to the manufacturer's instructions. DAPI staining was used to determine the number of nuclei and to assess gross cell morphology.
In vivo assay
Female BALB/c athymic nude mice (6-week-old) (Institute of Zoology, Chinese Academy of Sciences) were used for in vivo study. A total of 1×10 6 HEp-2 cells transfected with miR-21 ASO or control ASO, as well as the non-transfected HEp-2 cells, were implanted subcutaneously in the right armpit of nude mice. Each group consisted of six mice. Tumor volumes were measured from the first 6 days, and once every other day. Tumor volume was calculated from (length × width 2 )/2 and presented as mean ± standard deviation (SD) mm 3 [31] . Statistical analysis was performed using the Student's t-test to compare the tumor volume between different treatment groups.
Semi-quantitative RT-PCR
Total RNAs were extracted from transfected HEp-2 cells for semi-quantitative RT-PCR (sqRT-PCR) at 48 h post-transfection. Target genes and the endogenous control gene, β-actin, were included in the same reaction. PCR products were electrophoresed on 1% agarose gels containing ethidium bromide and visualized under UV transilluminator. Bands were quantified with Labworks 4.0 software.
Western blot
Total protein from HEp-2 cells transfected with either oligonucleotides or plasmids was extracted using RIPA buffer (1 mM MgCl 2 , 10mM Tris-HCl pH 7.4, 1% Triton X-100, 0.1% SDS, 1%NP-40), and protein expression was analyzed by western blot. β-Tubulin was served as a loading control. Total protein extracts were separated on 12% SDS-PAGE gels and transferred to nitrocellulose membranes. The level of BTG2 expression was evaluated using the rabbit polyclonal anti-BTG2 antibody (Saier Biotech, Tianjin, China), which is immunogen affinity purified. As a loading control, the β-tubulin expression level was measured using rabbit polyclonal anti-β-tubulin antibody (Sigma-Aldrich, MO, USA). Bands were quantified with Labworks 4.0 software.
EGFP reporter assay
The HEp-2 cells were seeded in 24-well plates and cotransfected with 700 ng of the fluorescence reporter plasmid, 300 ng of the pDsRed2-N1 plasmid (as a control for transfection efficiency), and 100 pmol of oligonucleotides or 500 ng of the miRNA-expressing construct using Lipofectamine 2000 reagent (Invitrogen). At 48 h after transfection, EGFP and RFP (red fluorescent protein) activities were measured with the F-4500 fluorescence spectrophotometer (HITACHI, Japan). The EGFP value was normalized by the RFP value.
Statistical analysis
